Literature DB >> 16984691

ErbB receptors and their ligands in the breast.

Cynthia A Zahnow1.   

Abstract

ErbB receptor tyrosine kinases are membrane-bound receptors that possess intrinsic, ligand-activated, tyrosine kinase activity. Binding of growth factors to these receptors induces the formation of ErbB homo- and heterodimers and initiates a signalling cascade that traverses the cytoplasm to communicate with the nucleus and the cytoskeleton. The effect of this cascade is the regulation of cellular proliferation, differentiation, apoptosis, migration and adhesion. Although ErbB signalling is important for normal growth and development in the breast, a dysregulation of ErbB activity can lead to tumourigenesis. This review will focus on the role of ErbB signalling in both normal mammary gland development and breast cancer, with an emphasis on the mechanisms behind receptor activation and the therapeutic agents designed to inhibit ErbB activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16984691     DOI: 10.1017/S146239940600010X

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  11 in total

Review 1.  CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases.

Authors:  Cynthia A Zahnow
Journal:  Expert Rev Mol Med       Date:  2009-04-08       Impact factor: 5.600

2.  Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.

Authors:  Thomas Frogne; Rikke V Benjaminsen; Katrine Sonne-Hansen; Boe S Sorensen; Ebba Nexo; Anne-Vibeke Laenkholm; Louise M Rasmussen; David J Riese; Patricia de Cremoux; Jan Stenvang; Anne E Lykkesfeldt
Journal:  Breast Cancer Res Treat       Date:  2008-04-14       Impact factor: 4.872

Review 3.  The role of NRG3 in mammary development.

Authors:  Beatrice A Howard
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-17       Impact factor: 2.673

4.  Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy.

Authors:  Mathilde S Larsen; Karsten Bjerre; Anne E Lykkesfeldt; Anita Giobbie-Hurder; Anne-Vibeke Laenkholm; Katrine L Henriksen; Bent Ejlertsen; Birgitte B Rasmussen
Journal:  Breast       Date:  2012-07-31       Impact factor: 4.380

5.  Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis.

Authors:  Hao Liao; Wenfa Huang; Yaxin Liu; Wendi Pei; Huiping Li
Journal:  Front Oncol       Date:  2021-05-03       Impact factor: 6.244

6.  LIP expression is regulated by IGF-1R signaling and participates in suppression of anoikis.

Authors:  Huili Li; Brenda R Baldwin; Cynthia A Zahnow
Journal:  Mol Cancer       Date:  2011-08-19       Impact factor: 27.401

7.  Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis.

Authors:  Qiuyan Yu; Zhenli Zhu; Yan Liu; Jun Zhang; Ke Li
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

8.  Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.

Authors:  Bing-He Xu; Ze-Fei Jiang; Daniel Chua; Zhi-Min Shao; Rong-Cheng Luo; Xiao-Jia Wang; Dong-Geng Liu; Winnie Yeo; Shi-Ying Yu; Beth Newstat; Alka Preston; Anne-Marie Martin; Hai-Dong Chi; Li Wang
Journal:  Chin J Cancer       Date:  2011-05

Review 9.  Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.

Authors:  Magdalena Malm; Fredrik Y Frejd; Stefan Ståhl; John Löfblom
Journal:  MAbs       Date:  2016-08-17       Impact factor: 5.857

10.  Inhibitory Effect of Polyclonal Antibodies Against HER3 Extracellular Subdomains on Breast Cancer Cell Lines.

Authors:  Samaneh Mansouri-Fard; Mojgan Ghaedi; Mohammad-Reza Shokri; Tannaz Bahadori; Jalal Khoshnoodi; Forough Golsaz-Shirazi; Mahmood Jeddi-Tehrani; Mohammad Mehdi Amiri; Fazel Shokri
Journal:  Asian Pac J Cancer Prev       Date:  2020-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.